Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 8/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.52 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38659727 | 1.00 | ALDH1A1 (0.54) | ALDH1A1MEN1KMT2AESR1LMNA | |
| SCHEMBL4179934 | 0.86 | SRD5A1 (0.55) | ALDH1A1MEN1KMT2AESR1LMNA | |
| SCHEMBL33098 | 0.85 | MAOB (0.43) | ALDH1A1MEN1KMT2AESR1LMNA | |
| SCHEMBL3029410 | 0.79 | PRF1 (0.56) | ALDH1A1MEN1KMT2AESR1LMNA | |
| SCHEMBL11838162 | 0.79 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2AESR1LMNA | |
| SCHEMBL11852789 | 0.79 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2AESR1LMNA | |
| SCHEMBL17332073 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MEN1KMT2AESR1LMNA | |
| SCHEMBL31532073 | 0.78 | SRD5A1 (0.51) | ALDH1A1KMT2ASMN1; SMN2HPGDSRD5A1 | |
| SCHEMBL883773 | 0.78 | SRD5A1 (0.51) | ALDH1A1KMT2ASMN1; SMN2HPGDSRD5A1 | |
| SCHEMBL552474 | 0.78 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AESR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803951-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1626717-A4 | BENZIMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7563815-B2 | Benzamidazoles, compositions containing such compounds and methods of use | MERCK & CO., INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090054506-A1 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME LLC | 2009-02-26 | — | — | US | disclosed |
| EP-1868985-A2 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070093544-A1 | 1-((4-Tert-butylcyclohexyl)(1-methyl-5-propoxy-1H-benzimidazol-2-yl-amino-)-N-1H-tetrazole-5-yl-indane-5-carboxamide; glucagon receptor antagonists; antidiabetic agents; type 2 diabetes mellitus; insulin resistance; gluconeogenesis inhibitors; lowering rate of hepatic glucose output; hypoglycemic agents | MERCK SHARP & DOHME LLC | 2007-04-26 | — | — | US | disclosed |
| WO-2006104826-A2 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1626717-A2 | BENZIMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004100875-A2 | BENZIMIDAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093544-A1 | 1-((4-Tert-butylcyclohexyl)(1-methyl-5-propoxy-1H-benzimidazol-2-yl-amino-)-N-1H-tetrazole-5-yl-indane-5-carboxamide; glucagon receptor antagonists; antidiabetic agents; type 2 diabetes mellitus; insulin resistance; gluconeogenesis inhibitors; lowering rate of hepatic glucose output; hypoglycemic agents | GPR119, GLP1R, INSR | ALDH1A1 2026/4885MEN1 4418/4885KMT2A 2904/4885 |
| US-20090054506-A1 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | GCGR, GLP1R, GPR119 | ALDH1A1 4286/4885MEN1 2045/4885KMT2A 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.